
ETNB
Healthcare · Biotechnology · $2.20B market cap
Latest report
Time not confirmed
The next earnings date isn’t on the calendar yet.
Analyst consensus
Analyst estimates aren’t available for this symbol.
Beat estimates in 3 of the last 4 reported quarters.
EPS surprise versus the estimate at the time of the report.
| Date | Session | Estimate | Actual | Surprise |
|---|---|---|---|---|
| Mar 25, 2026 | Time not confirmed | -0.52 | 0.00 | +100.0% |
| Nov 6, 2025 | Time not confirmed | -0.51 | 0.00 | +100.0% |
| Aug 8, 2025 | Time not confirmed | -0.50 | -0.71 | -42.0% |
| May 7, 2025 | Before the open | -0.57 | -0.49 | +13.3% |
| Feb 26, 2025 | Before the open | -0.76 | -1.02 | -34.3% |
| Nov 6, 2024 | After the close | -0.64 | -1.39 | -117.2% |
| Aug 5, 2024 | After the close | -0.57 | -0.48 | +15.8% |
| May 9, 2024 | After the close | -0.46 | -0.54 | -17.4% |
| Feb 29, 2024 | After the close | -0.49 | -0.50 | -2.0% |
| Nov 8, 2023 | After the close | -0.53 | -0.45 | +15.1% |
| Aug 9, 2023 | After the close | -0.41 | -0.52 | -26.8% |
| May 4, 2023 | After the close | -0.52 | -0.54 | -3.8% |
| Mar 10, 2023 | Before the open | -0.69 |
89bio, Inc., a clinical-stage biopharmaceutical company, engages in the development and commercialization of therapies for the treatment of liver and cardio-metabolic diseases. Its lead product candidate is pegozafermin, a glycoPEGylated analog of fibroblast growth factor 21 for the treatment of metabolic dysfunction-associated steatohepatitis and hypertriglyceridemia. 89bio, Inc. was formerly known as The company…
| -0.48 |
| +30.4% |
| Nov 10, 2022 | After the close | -0.80 | -0.57 | +28.8% |
| Aug 11, 2022 | Before the open | -1.05 | -1.23 | -17.1% |
| May 11, 2022 | After the close | -1.29 | -1.26 | +2.3% |
| Mar 24, 2022 | After the close | -1.31 | -1.30 | +0.8% |
| Nov 11, 2021 | After the close | -1.06 | -1.41 | -33.0% |
| Aug 12, 2021 | After the close | -0.84 | -1.03 | -22.6% |
| May 12, 2021 | After the close | -0.69 | -0.74 | -7.2% |
| Mar 24, 2021 | After the close | -0.87 | -0.63 | +27.6% |
| Nov 10, 2020 | After the close | -0.84 | -0.86 | -2.4% |
| Aug 13, 2020 | After the close | -0.83 | -0.85 | -2.4% |
| May 13, 2020 | After the close | -0.86 | -0.76 | +11.6% |
| Mar 18, 2020 | After the close | -0.94 | -2.58 | -174.5% |
| Dec 18, 2019 | After the close | -1.20 | -30.63 | -2452.5% |